OBJECTIVES: Quizartinib is an oral, potent, selective, type II FLT3 inhibitor with prolonged OS as a single-agent in relapsed/refractory FLT3-ITD+ AML. We report results from the global, randomized, double-blind, phase 3 QuANTUM-First trial (NCT02668653), evaluating quizartinib plus standard induction and post-remission consolidation (including allogeneic hematopoietic cell transplant [allo-HCT] in first complete remission [CR1]) followed by single-agent continuation (up to 3 years) vs placebo plus chemotherapy in newly diagnosed FLT3-ITD+ AML. METHODS: Patients 18-75 years with newly diagnosed FLT3-ITD+ AML received induction with cytarabine 100 or 200 mg/m2/day (days 1-7) and daunorubicin 60 mg/m2/day or idarubicin 12 mg/m2/day (days 1-3). Patients were randomized to quizartinib (40 mg/day [days 8-21]) or placebo; stratified by region, age, and white blood cell count at diagnosis. Patients with CR or CR with incomplete hematologic recovery (CRi) received up to 4 cycles of high-dose cytarabine plus quizartinib (40 mg/day) or placebo and/or allo-HCT followed by continuation with quizartinib (30-60 mg/day) or placebo (up to 3 years). The primary endpoint was OS. RESULTS: Between September 2016 and August 2019, 539 patients were randomized (quizartinib [n=268], placebo [n=271]). Median age was 56 years (range, 20-75 years). As of August 2021 (median follow-up, 39.2 months), 58 patients remained on continuation. Median OS was significantly longer with quizartinib vs placebo (31.9 vs 15.1 months; HR, 0.776; 95% CI, 0.615-0.979; 2-sided P=.0324). CR+CRi rates were 71.6% and 64.9%, respectively. Allo-HCT in CR1 was performed in 157 patients (quizartinib, 31%; placebo, 27%). When censored for allo-HCT, OS trended longer with quizartinib vs placebo (HR, 0.752; 95% CI, 0.562-1.008; 2-sided P=.055). Relapse-free survival was longer with quizartinib vs placebo (HR, 0.733; 95% CI, 0.554-0.969). Grade ≥3 adverse events (AEs) were similar across arms. Discontinuations due to AEs occurred in 20.4% (quizartinib) and 8.6% (placebo). Fifty-six patients died from treatment-emergent AEs (quizartinib, 11.3%; placebo, 9.7%); mostly infections. Grade 3/4 electrocardiographic QT prolongation occurred in 3.0% (quizartinib) and 1.1% (placebo). CONCLUSIONS: Quizartinib plus standard therapy, followed by continuation, including after allo-HCT, for up to 3 years was tolerable with statistically significant and clinically meaningful OS improvements in adults ≤75 years with newly diagnosed FLT3-ITD+ AML.

Augusta University Medical Center Augusta GA USA

Chang Gung Medical Foundation Linkou Taiwan

Daiichi Sankyo Inc Basking Ridge NJ USA

Daiichi Sankyo UK Ltd Uxbridge United Kingdom

Duke Cancer Institute Durham NC USA

Heidelberg University Hospital and German Cancer Research Center Heidelberg Germany

Institute of Hematology and Blood Diseases Hospital Tianjin China

Institute of Hematology and Blood Transfusion Warsaw Poland

Johns Hopkins University Baltimore MD USA

La Fe University and Polytechnic Hospital Valencia Spain

Saint Louis Hospital University of Paris Paris France

Sylvester Cancer Center University of Miami Health System Miami FL USA

The Catholic University of Korea Seoul St Mary's Hospital Seoul Korea Republic of

Tor Vergata Polyclinic Hospital Rome Rome Italy

University Hospital Centre Zagreb Zagreb Croatia

University Hospital Hradec Kralove Hradec Kralove Czech Republic

University of Pennsylvania Philadelphia PA USA

000      

00000naa a2200000 a 4500

001      

bmc22024259

003      

CZ-PrNML

005      

20240418103301.0

007      

ta

008      

221017s2022 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1016/S2152-2650(22)01212-5 $2 doi

035    __

$a (PubMed)36163755

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Erba, Harry $u Duke Cancer Institute, Durham, NC, USA

245    10

$a AML-029 Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3-Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) / $c H. Erba, P. Montesinos, R. Vrhovac, E. Patkowska, HJ. Kim, P. Zak, PN. Wang, T. Mitov, J. Hanyok, L. Liu, A. Benzohra, A. Lesegretain, J. Cortes, A. Perl, M. Sekeres, H. Dombret, S. Amadori, J. Wang, M. Levis, R. Schlenk

520    9_

$a OBJECTIVES: Quizartinib is an oral, potent, selective, type II FLT3 inhibitor with prolonged OS as a single-agent in relapsed/refractory FLT3-ITD+ AML. We report results from the global, randomized, double-blind, phase 3 QuANTUM-First trial (NCT02668653), evaluating quizartinib plus standard induction and post-remission consolidation (including allogeneic hematopoietic cell transplant [allo-HCT] in first complete remission [CR1]) followed by single-agent continuation (up to 3 years) vs placebo plus chemotherapy in newly diagnosed FLT3-ITD+ AML. METHODS: Patients 18-75 years with newly diagnosed FLT3-ITD+ AML received induction with cytarabine 100 or 200 mg/m2/day (days 1-7) and daunorubicin 60 mg/m2/day or idarubicin 12 mg/m2/day (days 1-3). Patients were randomized to quizartinib (40 mg/day [days 8-21]) or placebo; stratified by region, age, and white blood cell count at diagnosis. Patients with CR or CR with incomplete hematologic recovery (CRi) received up to 4 cycles of high-dose cytarabine plus quizartinib (40 mg/day) or placebo and/or allo-HCT followed by continuation with quizartinib (30-60 mg/day) or placebo (up to 3 years). The primary endpoint was OS. RESULTS: Between September 2016 and August 2019, 539 patients were randomized (quizartinib [n=268], placebo [n=271]). Median age was 56 years (range, 20-75 years). As of August 2021 (median follow-up, 39.2 months), 58 patients remained on continuation. Median OS was significantly longer with quizartinib vs placebo (31.9 vs 15.1 months; HR, 0.776; 95% CI, 0.615-0.979; 2-sided P=.0324). CR+CRi rates were 71.6% and 64.9%, respectively. Allo-HCT in CR1 was performed in 157 patients (quizartinib, 31%; placebo, 27%). When censored for allo-HCT, OS trended longer with quizartinib vs placebo (HR, 0.752; 95% CI, 0.562-1.008; 2-sided P=.055). Relapse-free survival was longer with quizartinib vs placebo (HR, 0.733; 95% CI, 0.554-0.969). Grade ≥3 adverse events (AEs) were similar across arms. Discontinuations due to AEs occurred in 20.4% (quizartinib) and 8.6% (placebo). Fifty-six patients died from treatment-emergent AEs (quizartinib, 11.3%; placebo, 9.7%); mostly infections. Grade 3/4 electrocardiographic QT prolongation occurred in 3.0% (quizartinib) and 1.1% (placebo). CONCLUSIONS: Quizartinib plus standard therapy, followed by continuation, including after allo-HCT, for up to 3 years was tolerable with statistically significant and clinically meaningful OS improvements in adults ≤75 years with newly diagnosed FLT3-ITD+ AML.

650    _2

$a dospělí $7 D000328

650    _2

$a benzothiazoly $7 D052160

650    _2

$a chemoterapie konsolidační $7 D060830

650    _2

$a cytarabin $x terapeutické užití $7 D003561

650    _2

$a daunomycin $x terapeutické užití $7 D003630

650    12

$a transplantace hematopoetických kmenových buněk $x metody $7 D018380

650    _2

$a lidé $7 D006801

650    _2

$a idarubicin $x terapeutické užití $7 D015255

650    12

$a akutní myeloidní leukemie $x farmakoterapie $x genetika $7 D015470

650    _2

$a lidé středního věku $7 D008875

650    _2

$a fenylmočovinové sloučeniny $7 D010671

650    _2

$a tyrosinkinasa 3 podobná fms $x genetika $7 D051941

655    _2

$a klinické zkoušky, fáze III $7 D017428

655    _2

$a časopisecké články $7 D016428

655    _2

$a randomizované kontrolované studie $7 D016449

700    1_

$a Montesinos, Pau $u La Fe University and Polytechnic Hospital, Valencia, Spain

700    1_

$a Vrhovac, Radovan $u University Hospital Centre Zagreb, Zagreb, Croatia

700    1_

$a Patkowska, Elzbieta $u Institute of Hematology and Blood Transfusion, Warsaw, Poland

700    1_

$a Kim, Hee-Je $u The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of

700    1_

$a Zak, Pavel $u University Hospital Hradec Kralove, Hradec Kralove, Czech Republic

700    1_

$a Wang, Po-Nan $u Chang Gung Medical Foundation, Linkou, Taiwan

700    1_

$a Mitov, Tsvetomir $u Daiichi Sankyo UK Ltd, Uxbridge, United Kingdom

700    1_

$a Hanyok, James $u Daiichi Sankyo, Inc, Basking Ridge, NJ, USA

700    1_

$a Liu, Li $u Daiichi Sankyo, Inc, Basking Ridge, NJ, USA

700    1_

$a Benzohra, Aziz $u Daiichi Sankyo, Inc, Basking Ridge, NJ, USA

700    1_

$a Lesegretain, Arnaud $u Daiichi Sankyo, Inc, Basking Ridge, NJ, USA

700    1_

$a Cortes, Jorge $u Augusta University Medical Center, Augusta, GA, USA

700    1_

$a Perl, Alexander $u University of Pennsylvania, Philadelphia, PA, USA

700    1_

$a Sekeres, Mikkael $u Sylvester Cancer Center, University of Miami Health System, Miami, FL, USA

700    1_

$a Dombret, Hervé $u Saint Louis Hospital, University of Paris, Paris, France $7 xx0316388

700    1_

$a Amadori, Sergio $u Tor Vergata Polyclinic Hospital Rome, Rome, Italy

700    1_

$a Wang, Jianxiang $u Institute of Hematology and Blood Diseases Hospital, Tianjin, China

700    1_

$a Levis, Mark $u Johns Hopkins University, Baltimore, MD, USA

700    1_

$a Schlenk, Richard $u Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany

773    0_

$w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 22 Suppl 2 (2022), s. S208-S209

856    41

$u https://pubmed.ncbi.nlm.nih.gov/36163755 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20221017 $b ABA008

991    __

$a 20240418103255 $b ABA008

999    __

$a ok $b bmc $g 1854148 $s 1175549

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2022 $b 22 Suppl 2 $c - $d S208-S209 $e - $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199

LZP    __

$a Pubmed-20221017